Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. - sprookjes - yvandenbroek - TriplyDB

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.

http://www.wikidata.org/entity/Q33374964

about

Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment.Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study Novel inhibitors of AKT: assessment of a different approach targeting the pleckstrin homology domain.Bortezomib in multiple myeloma: systematic review and clinical considerations.Compromising the unfolded protein response induces autophagy-mediated cell death in multiple myeloma cells.A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.Proteasome inhibitors in the treatment of multiple myeloma Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma.Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012 Bortezomib in mantle cell lymphoma.Treatment of relapsed and refractory myeloma.Toxicity of targeted therapies in elderly patients.Extramedullary relapse of IgA-lambda myeloma after recent bortezomib therapy: a case report.Cx43 expressed on bone marrow stromal cells plays an essential role in multiple myeloma cell survival and drug resistance Managing multiple myeloma in the elderly: are we making progress?New Treatment Approaches for Older Adults with Multiple Myeloma.Incorporating novel agents in the management of elderly myeloma patients.Anti-galectin-3 therapy: a new chance for multiple myeloma and ovarian cancer?A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma.Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors.Patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic model.Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells.Changes in the survival of older patients with hematologic malignancies in the early 21st century.Patterns and effectiveness of bortezomib use according to age in the VESUVE cohort.Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model Outcomes of primary refractory multiple myeloma and the impact of novel therapies.Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression.Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis.Multiple myeloma in the very old: an IASIA conference report.Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma.Living with Relapsed Myeloma: Symptoms and Self-care Strategies.Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma

P2860

Q28742668-77139731-5DA6-4FCB-8497-B2DC1FE3C501 Q33376918-CE3C0409-8FED-4474-B6FB-AB25945B48ED Q33388541-D56541FB-4771-4D98-8ABC-09B92F94CABA Q33415759-09995E9E-C569-4568-B2A4-B7AC2CD4A0BC Q33626064-3300A846-2120-40E7-9FFE-8238B6E4081B Q33882138-B2039BFF-5532-4D8B-950C-3A8BD84D46E1 Q33982728-3B97D81C-EAEE-4AEF-877A-A82DCA22086A Q34058325-F12A58D1-9AF0-4160-A9C6-B4EA4FF474A9 Q34134986-3C337557-691D-4709-8B11-455FC98446DE Q34611676-BEB662E1-BE75-44A9-ACFD-5B1E47A48A94 Q36407209-28CF51BF-950F-40B4-9DDF-F24BAC2E0D29 Q36897035-A5EA7145-8C3F-4B0F-A55C-691E7694AE6E Q37057028-D2ED1EE2-F438-4324-919B-D4E066C5DF0A Q37136989-1572EF2C-80E5-4ED9-85D4-F62CB562FAAA Q37209929-4534ABA7-8B23-4013-97D0-777D19AF97F3 Q37338263-F15801E0-E329-4416-A304-A78B1EDA3B56 Q37403468-450AC9A5-B6BF-4E64-BF48-7ACC3CB62DE6 Q37549419-82827AA0-90CA-404E-A87F-AC6791B794DB Q37888716-E9BCFE3F-481B-4002-9E42-6B1745B2B883 Q38048281-7982348D-B251-43C0-B07D-CB581BCF6574 Q38146974-765D52A4-9152-4C43-ADF4-F3131152933A Q38209789-79452B56-9F6F-42E7-BA2B-64C65B822CE5 Q38700339-31AAE823-4732-42A4-BDAD-ED09EB35FE6F Q38808490-107F358F-0C30-4FBB-AAE2-301A0B43EEB0 Q38947433-C07CF555-DF31-4778-A59E-D2E90D745C79 Q39184945-CCBF9EAF-5A8A-413A-8744-ABE69FE938D0 Q39779257-4CCAE85F-9B92-42C1-9F8D-84B98624F570 Q40511222-3A42D06D-E998-45B0-8807-767C43B07CF4 Q40550633-444BFCAF-375C-47CA-B839-3DAE66EED90B Q41543966-1EF11D48-5C15-4EFD-8055-794AC7319978 Q41874321-BAE0EE10-D0AB-4D0A-A267-BC907D5A1434 Q41915878-13A2C7F7-6017-41DF-A0F9-85971E74EF6C Q42094139-203E66BB-CE30-4027-B695-FC73F905E157 Q42122199-4A5E6E03-1F39-489D-9DD5-AB974F64DF74 Q43242121-98A91048-8F1D-4D35-94AA-3B2B9D095BEE Q46735730-FF350E53-84BD-4407-BFE3-9DE9ECD0F46B Q47269187-57576E1E-1C2A-4B49-84EA-B37DA78C3C7D Q53179212-6E1082F5-0D94-4CBF-8BB7-C8A14A501805 Q56982314-F8252E65-CD33-4091-A850-7A97DD91625F

P2860

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.

http://www.wikidata.org/entity/Q33374964

description

2007 nî lūn-bûn

@nan

2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Safety and efficacy of bortezo ...... ith relapsed multiple myeloma.

@ast

Safety and efficacy of bortezo ...... ith relapsed multiple myeloma.

@en

type

label

Safety and efficacy of bortezo ...... ith relapsed multiple myeloma.

@ast

Safety and efficacy of bortezo ...... ith relapsed multiple myeloma.

@en

prefLabel

Safety and efficacy of bortezo ...... ith relapsed multiple myeloma.

@ast

Safety and efficacy of bortezo ...... ith relapsed multiple myeloma.

@en

P1433

Q33374964-0C3E28BC-A8B1-4DC4-8994-1A9DA2AA3A03

P1476

Q33374964-D9E8C1A1-8A12-4589-9DC6-51CCADBAAD24

P2093

Q33374964-11320C35-A757-4E9F-BC78-F2E03CCFE2CA

Q33374964-327EF163-FD6F-4AE1-826C-63C098419483

Q33374964-362037BC-CA73-4416-8AB0-C9524600D56C

Q33374964-52D259C2-9852-4E99-A945-788816F7B86F

Q33374964-A25AA7D1-01E9-41D1-846D-E835BBC9753A

Q33374964-BD769C64-994F-4B90-B548-8A59B799300A

Q33374964-EDE943F8-769A-4EDD-8FF6-185446B1C309

P2860

Q33374964-15D242D8-347B-48CC-AF2B-E6670A7BF03A

Q33374964-21D75027-9650-491C-A0BF-4EF28C235736

Q33374964-72B4BC77-0E48-480D-9E09-3ACB13BBF28A

Q33374964-80B2D745-81BD-4241-8ACF-C3CB22DEA86E

Q33374964-A33A1DFD-158C-4DA3-9E0B-C4C5CB9B9F36

Q33374964-B051C05E-96C7-4096-8B41-2B0B54D49E43

Q33374964-C5BE80CA-E688-49BC-B69A-92355CD7E1CA

Q33374964-C7B3F416-43D8-479E-A540-D81CDD3A254E

Q33374964-C8666E22-3B25-4021-9D1F-AD4A16734276

Q33374964-D0876326-B0A3-4163-AEBD-CE65CB8F8893

P304

Q33374964-38C71DF4-1F0C-4953-B3E2-180D232B0754

P31

Q33374964-0281EEF6-E4BF-4F0F-A914-B2DDD69B7586

P356

Q33374964-89BA5F56-15D4-45AF-A853-9A37DF62C080

P407

Q33374964-A525C9FB-9949-4CC5-B44A-810C9738A27E

P433

Q33374964-FCEE959B-B6A7-41DA-8705-93E3AECBCFDE

P478

Q33374964-F953A8B2-F70B-4052-BB37-F826876F397E

P50

Q33374964-463710CB-F59D-4B86-BA4F-E952EAFCDF27

Q33374964-482D35D8-6D15-48BF-9382-E14F8482DFEA

Q33374964-4A405204-5D4B-4463-902B-E28857419127

Q33374964-835C8C23-8CEC-4FE9-8475-874F13C8F40E

Q33374964-859784B2-DFE7-4645-AA07-FC6B1A6D9F0F

Q33374964-96187199-A2A6-4AE9-8D38-31F426230EE4

P577

Q33374964-EA4A94A0-3106-4E72-9E89-7AEADC6B75DE

P5875

Q33374964-4E6FB6B7-8AC9-46EF-82BE-F57210BBD454

P698

Q33374964-D9FC979D-7BC9-451E-9221-910EC3469981

P356

J.1365-2141.2007.06585.X

P1433

British Journal of Haematology

P1476

Safety and efficacy of bortezo ...... ith relapsed multiple myeloma.

@en

P2093

David Irwin

http://www.w3.org/2001/XMLSchema#string

Dina Ben-Yehuda

http://www.w3.org/2001/XMLSchema#string

Edward A Stadtmauer

http://www.w3.org/2001/XMLSchema#string

Jamie D Cavenagh

http://www.w3.org/2001/XMLSchema#string

Jean-Luc Harousseau

http://www.w3.org/2001/XMLSchema#string

Jesús-F San Miguel

http://www.w3.org/2001/XMLSchema#string

Michael W Schuster

http://www.w3.org/2001/XMLSchema#string

P2860

A phase 2 study of bortezomib in relapsed, refractory myeloma.

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.

Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.

United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.

Treatment of multiple myeloma in elderly people: long-term results in 178 patients.

International staging system for multiple myeloma.

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

The adverse prognostic impact of advanced age in multiple myeloma.

Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.

P304

429-435

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2141.2007.06585.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

137

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth C Anderson

Pieter Sonneveld

Paul G Richardson

P577

2007-04-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6378350

http://www.w3.org/2001/XMLSchema#string

P698

17451408

http://www.w3.org/2001/XMLSchema#string